Table 1.

Patient Characteristics and Outcomes

PatientAgeSexKaryotype and molecular findings% Marrow blasts at diagnosisDay 14 bone marrowInduction outcomePostinduction therapy and outcome
100263M+8, t(9:11), FLT3 TKD93<5% cellularity; NEDCRThree cycles of IDAC consolidation off study followed by allogeneic stem cell transplant in CR1.
100346Mt(12,13)6.4<5% cellularity; NEDFailureAllogeneic transplant after salvage therapy.
100474Madd(8) t(8,19) FLT3 TKD64Suboptimal; NEDCRTwo cycles of IDAC consolidation and relapse 6 mo after diagnosis.
Postrelapse therapy on an experimental protocol and died of cerebral hemorrhage.
100546MXY (SNP array)26Suboptimal; serous atrophy; NEDCRFour cycles of HiDAC + CX-01 consolidation on study.
Relapse 16 mo after diagnosis. Underwent salvage therapy and allogeneic transplant. Had extramedullary relapse posttransplant and underwent salvage therapy and donor lymphocyte infusion.
100671Finv(3) FLT3 ITD59<5% cellularity; serous atrophy; NEDCR MRDTwo cycles of IDAC consolidation off study followed by allogeneic stem cell transplant in CR1.
Relapse 9 mo after diagnosis, received further therapy on an experimental protocol and died of infectious complications.
100758Minv(16) +8, +22, +2151<5% cellularity serous atrophy; NEDCR MRDFour cycles of HiDAC consolidation off study because of incomplete induction cycle.
100954MXY - NPM1+3710% cellularity; NEDCRThree cycles of consolidation with HiDAC + CX-01 on study
One cycle of consolidation with HiDAC alone after withdrawing from study.
101052MXY - FLT3 ITD30<5% cellularity serous atrophy; NEDCRDeveloped line-associated deep vein thrombosis and went off study after induction. –
Two cycles of HiDAC consolidation off study followed by allogeneic stem cell transplant in CR1.
200154Mt(6,9) - FLT3 ITD70Not doneCRReceived 2 d of induction and relapsed 7 wk after diagnosis.
Underwent salvage therapy and allogeneic stem cell transplant. Subsequently died of transplant-related complications.
300122FXX - NPM1 +21<10% cellularity; NEDCROne cycle of HiDAC + CX-01 consolidation on study and was lost to follow-up after withdrawing study.
Relapsed 13.5 mo after diagnosis, received salvage therapy and underwent allogeneic stem cell transplant in second remission.
300267Mdel(20) (q11.2) - FLT3 ITD (tested at relapse)50Hypocellular; NEDCRThree cycles of consolidation therapy off study.
Relapsed 11.5 mo after diagnosis. Underwent salvage therapy with transient response and relapse followed by allogeneic stem cell transplant.
300325FXX69<20% cellularity; NEDCRTwo cycles of HiDAC + CX-01 consolidation on study.
Relapsed 6 mo after diagnosis and underwent salvage therapy and allogeneic stem cell transplant. Subsequently relapsed again and underwent salvage and second allogeneic stem cell transplant and died of transplant-related complications.
  • HiDAC, high-dose cytarabine; IDAC, intermediate-dose cytarabine; MRD, minimal residual disease; NED, no evidence of disease.